Spots Global Cancer Trial Database for Studying DNA in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Studying DNA in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer
Official Title: DNA Methylation as a Predictor for Response and Progression-Free Survival in Patients With Ovarian Cancer
Study ID: NCT00900289
Conditions
Study Description
Brief Summary: RATIONALE: Studying tissue and blood samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients respond to treatment. PURPOSE: This laboratory study is evaluating DNA to see how well it predicts response to treatment in patients with stage I, stage II, stage III, or stage IV ovarian epithelial cancer.
Detailed Description: OBJECTIVES: * To determine if DNA methylation patterns and expression of differentially methylated genes taken before chemotherapy can predict patient outcome with regard to progression-free survival. * To evaluate whether DNA methylation can predict response assessed by RECIST criteria and CA 125 response. * To evaluate the specificity and sensitivity of predicting methylation changes in tumor from the changes at the corresponding CpG islands in plasma. OUTLINE: Tumor samples are collected at the time of initial laparotomy and blood is drawn prior to surgery for DNA methylation and biomarker studies. Changes in DNA methylation will be examined globally using DNA methylation hybridization to microarrays and methylation specific PCR, as well as expression of genes shown to be differentially methylated.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Basildon University Hospital, Basildon, England, United Kingdom
St. Michael's Hospital, Bristol, England, United Kingdom
Queens Hospital, Burton-upon-Trent, England, United Kingdom
Gloucestershire Oncology Centre at Cheltenham General Hospital, Cheltenham, England, United Kingdom
Essex County Hospital, Colchester, England, United Kingdom
Derbyshire Royal Infirmary, Derby, England, United Kingdom
Gloucestershire Royal Hospital, Gloucester, England, United Kingdom
Hereford Hospitals, Hereford, England, United Kingdom
Princess Royal Hospital at Hull and East Yorkshire NHS Trust, Hull, England, United Kingdom
Ipswich Hospital, Ipswich, England, United Kingdom
Barts and the London NHS Trust, London, England, United Kingdom
Hammersmith Hospital, London, England, United Kingdom
Mid Kent Oncology Centre at Maidstone Hospital, Maidstone, England, United Kingdom
James Cook University Hospital, Middlesbrough, England, United Kingdom
Milton Keynes General Hospital, Milton Keynes, England, United Kingdom
Norfolk and Norwich University Hospital, Norwich, England, United Kingdom
Derriford Hospital, Plymouth, England, United Kingdom
Dorset Cancer Centre, Poole Dorset, England, United Kingdom
Stirling Royal Infirmary, Stirling, England, United Kingdom
Taunton and Somerset Hospital, Taunton Somerset, England, United Kingdom
Royal Cornwall Hospital, Truro, Cornwall, England, United Kingdom
Southend University Hospital NHS Foundation Trust, Westcliff-On-Sea, England, United Kingdom
Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom
Ninewells Hospital, Dundee, Scotland, United Kingdom
Edinburgh Cancer Centre at Western General Hospital, Edinburgh, Scotland, United Kingdom
Royal Infirmary - Castle, Glasgow, Scotland, United Kingdom
Contact Details
Name: Nadeem Siddiqui, MD
Affiliation: Scottish Gynaecological Cancer Trials Group
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
